SCHEMBL31395363

SCHEMBL31395363

Fc1ccc(Oc2ncncc2Br)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 3/20 0.49
▸ ALDH1A1 P00352 3/20 0.42
▸ MRGPRX1 Q96LB2 1/20 0.42
▸ MEN1 O00255 3/20 0.40
▸ KMT2A Q03164 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ FLT3 P36888 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ CA12 O43570 1/20 0.38
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA9 Q16790 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ EGFR P00533 2/20 0.37
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20406319 0.83 APP (0.35) TRPA1FLT3EGFRCYP2C9SMN1; SMN2
SCHEMBL20406321 0.80 ALDH1A1 (0.36) TRPA1ALDH1A1MEN1KMT2AKDM4E
SCHEMBL31395403 0.77 TRPA1 (0.43) TRPA1ALDH1A1MRGPRX1MEN1KMT2A
SCHEMBL20406320 0.76 EGFR (0.32) TRPA1FLT3EGFRSMN1; SMN2KDR
SCHEMBL20406318 0.76 ICAM1 (0.38) TRPA1ALDH1A1FLT3EGFRSMN1; SMN2
SCHEMBL29415410 0.76 MEN1 (0.51) TRPA1ALDH1A1MRGPRX1MEN1KMT2A
SCHEMBL6611000 0.74 PTGER4 (0.46) MEN1KMT2AFLT3EGFR
SCHEMBL20406662 0.74 TRPA1 (0.33) TRPA1EGFRSMN1; SMN2KDR
SCHEMBL31395515 0.74 PDE10A (0.53) TRPA1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL20406664 0.71 CSF1R (0.34) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739307-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY The General Hospital Corporation (US) 2026-05-13 — — EP disclosed
WO-2025010291-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY THE GENERAL HOSPITAL CORPORATION (US) 2025-01-09 — — WO disclosed
Send feedback